Currently approved treatments for Fabry disease include intravenously delivered enzyme replacement therapy (ERT) with either agalsidase alfa, beta, or pegunigalsidase alfa, or oral treatment with migalastat, a first‐in‐class pharmacological chaperone treatment for patients with migalastat‐amenable GLA variants. The gene discussed is GLA; the disease is Fabry disease.